Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AGEN | Common Stock | Award | $595K | +237K | +30.75% | $2.51 | 1.01M | Feb 2, 2022 | Direct | F1, F2 |
holding | AGEN | Common Stock | 126K | Feb 2, 2022 | See Footnote | F3 | |||||
holding | AGEN | Common Stock | 579K | Feb 2, 2022 | See Footnote | F4 |
Id | Content |
---|---|
F1 | Reflects the executive's 2021 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a 6-month lockup restriction with 25% of the award released on the 3-month anniversary of the issuance date and 75% of the award released on the 6-month anniversary. |
F2 | $2.51 was the fair market value of our Common Stock on February 2, 2022, the stock issuance date. |
F3 | Shares are held in Dr. Armen's IRA accounts. |
F4 | Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 479,000 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 100,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein. |